Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Blaze Bioscience and Fred Hutchinson Cancer Research Center Collaborate

Published: Thursday, July 04, 2013
Last Updated: Thursday, July 04, 2013
Bookmark and Share
Collaboration leverages the Hutchinson Center’s research excellence with Blaze drug development expertise.

Blaze Bioscience, Inc. and Fred Hutchinson Cancer Research Center announced a collaboration and option agreement to support the Hutchinson Center’s Optides Discovery Program and advance drug candidates identified using the platform.

Optides, short for “optimized peptides,” are tiny molecules derived from natural organisms such as scorpions, violets and sunflowers. Optides can be instructed to bind to particular kinds of cancer cells, disabling only those cells. They also can be attached to chemotherapy drugs, transforming them into precision therapies that spare healthy cells.

Under the terms of the agreement, Blaze will provide development and commercialization guidance, as well as access to Blaze technology, for optide drug candidates during the discovery phase at the Hutchinson Center. Blaze has the option to exclusively license commercial rights to optide drug candidates that achieve certain criteria. In addition to technology access and support, the Hutchinson Center has received an additional equity stake in Blaze and will receive further payments on each product candidate optioned by Blaze. Any optide candidates not optioned by Blaze will belong fully to the Hutchinson Center including any intellectual property developed or provided by Blaze in the discovery phase for that optide candidate.

Blaze’s first development candidate, BLZ-100, is based on the first optide discovered by the Hutchinson Center. BLZ-100 is a variant of a peptide called chlorotoxin, which was originally derived from scorpion venom. This optide forms the backbone of the Tumor Paint technology previously licensed by Blaze.

“Collaborating on the Optides Program with the Hutchinson Center is a natural extension of our pipeline and utilizes our combined expertise,” said Heather Franklin, co-founder, president and chief executive officer of Blaze. “Our Tumor Paint technology program has maintained its aggressive schedule to advance BLZ-100 from license to clinic in just two years. Helping the Hutchinson Center quickly advance additional optide product candidates with efficient technology transfer followed by rapid entry into the clinic benefit both the Hutchinson Center and Blaze, but more importantly, may ultimately benefit patients.”

“We are pleased to establish this collaboration with Blaze. It is structured to efficiently match the Hutchinson Center’s superb discovery science with Blaze’s industry expertise in drug selection and peptide drug development in efforts to speed the transfer of Hutchinson Center optides discoveries to the clinic,” said Ulrich Mueller, vice president of Industry Relations and Clinical Research Support at the Hutchinson Center. “This will further the Hutchinson Center’s overarching mission to eliminate cancer and related diseases as causes of human suffering and death.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!